Comparison of the Effects of ShotBlocker, Virtual Reality Glasses and Cold Application in Subcutaneous Heparin Injection

NCT ID: NCT05833646

Last Updated: 2024-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2023-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the effects of ShotBlocker, virtual reality glasses and cold application on pain and patient satisfaction in patients who were applied subcutaneous low molecular weight heparin (LMWH) injection in adult patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research being carried out in Ankara City Hospital Clinic of Orthopedics. The research sample is expected to consist of 150 adult patients, who will be randomly divided into three groups. First group will be applied ShotBlocker (n=50); second group will be applied Virtual Reality Glasses (n=50) and third group will be applied subcutaneous LMWH via cold application (n=50). So as to assess the effect of the injection, it will be applied on patients' left side within abdomen site via standard method (control) while the same will be done on patients' right side according to method of intervention (intervention). Therefore, each patient will form both intervention and control groups. Prior to subcutaneous LMWH injection, "Descriptive Characteristics Form", which includes participants' socio-demographic attributes (gender, marital status, age, level of education, etc.), will be filled out by the researcher by means of face-to-face interview. Following the injection, in order to evaluate patients' pain, "Visual Analog Scale for Pain" will be filled while "Visual Analog Scale for Satisfaction" will be used in order to identify patients' satisfaction with the application. It is expected that compared to standard injection, ShotBlocker, virtual reality glasses and cold application will reveal more positive results on pain and patient satisfaction during subcutaneous LMWH injection in adult patients. Besides, the method that has the more effect will be determined by comparing different methods. It is thought the data collected by the research will contribute to literature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subcutaneous Injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Self-controlled, quasi-experimental
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ShotBlocker Group

In control application, subcutaneous (SC) LMWH injection will be applied in patient's left abdomen with standard method on Post-op 0th day by the researcher. Intervention with ShotBlocker will be performed on the right abdomen site on post-op 1st day by the researcher. During subcutaneous LMWH injection with ShotBlocker, suitable injection site in right abdomen will be grasped by applying medium-weight pressure as ShotBlocker's obtuse touching points would touch the skin. In order to avoid ecchymosis and hematoma, it will be applied slowly for 10 seconds by entering from the middle point of ShotBlocker with a 90° angle. When injection is over, ShotBlocker will be removed 10 seconds will be waited. Removing the needle, the entry point will be applied light pressure with dry cotton for 10 seconds without any massage. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.

Group Type EXPERIMENTAL

Group 1

Intervention Type DEVICE

In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.

Virtual Reality Glasses (VRG) Group

Standard LMWH application will be performed on the left side for control on Post-op 0th day by the researcher.

Intervention with VRG will be performed on the right abdomen site on post-op 1st day. The researcher will show the patient a video 5 minutes before the injection providing them with virtual reality glasses, which will continue till the end of the operation, after which the glasses will be removed. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.

Group Type EXPERIMENTAL

Group 2

Intervention Type DEVICE

In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.

Cold Application Group

Standard heparin application will be performed on left side for control on post-op 0th day by the researcher. Intervention with cold application will be performed on the right abdomen site on post-op 1st day. Prior to the intervention, cold silica gel pack which stayed in the freezer for at least 2 hours will be placed on patient's injection site by wrapping up with towel and will be applied on the site for 5 minutes. After 5 minutes, the cold gel pack will be removed from the site and subcutaneous LMWH injection will be applied by the researcher. Following the removal of the injector, cold application will continue for another 2 minutes. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) after injection.

Group Type EXPERIMENTAL

Group 3

Intervention Type DEVICE

In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group 1

In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.

Intervention Type DEVICE

Group 2

In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.

Intervention Type DEVICE

Group 3

In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ShotBlocker Virtual Reality Glasses (VRG) Cold Application

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Open to communication
* 18 or over years of age
* Received 1x0,4 ml enoksaparin sodium treatment
* Experienced no complications during or after operation
* Normal values of thrombocyte (150.000-300.000), aPTT (25-35 sec) and INR (0.8-1.2) (Thrombocyte, INR and aPTT tests will be assessed in accordance with reference values of the kits that the hospital uses.)
* No infection, scar tissue or incision in abdomen site
* Received no parenteral treatment other than this site
* Not diagnosed with any sort of coagulation disorder
* No visual impairment to be able to wear VR glasses
* No allergy to cold
* No mental or neurological disability
* No audio-visual impairment disability to be able to watch the video
* Turkish speaking and comprehending
* Non-pregnant
* No hematological or allergic disease
* Willing to be hospitalized for 2 days
* Volunteer to participate in the research will constitute the research sample.

Exclusion Criteria

During data collection, those who;

* Renounce from participating in the research
* Remove virtual reality glasses during or after operation
* Fail to hold the cold pack for necessary period of time
* Show signs of cold allergy during operation
* Change institutions or were discharged early during research
* Change dose of drugs within drug system
* Develop drawbacks in the abdomen site will be excluded from the research.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Yildirim Beyazıt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ebru Erek Kazan

Assoc.Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hafize Güllü, MsN

Role: PRINCIPAL_INVESTIGATOR

Ankara Yildirim Beyazit University , Faculty of Health Sciences, Department of Nursing

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara Yildirim Beyazit University Faculty of Health Sciences, Department of Nursing

Ankara, Çubuk, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-1790

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Therapeutic Normothermia in TBI
NCT06540768 NOT_YET_RECRUITING NA